The FDA granted Becton Dickinson premarket approval for its Venovo venous stent, a device designed to treat obstructed blood flow in the iliac and femoral veins.
The stent design balances radial strength, compression resistance and flexibility for the treatment of symptomatic post-thrombotic and non-thrombotic iliofemoral lesions.
The stent is available in a range of sizes to address the special challenges of iliofemoral lesions that are very different than those posed by arterial narrowing.
